Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Development (Cambridge, England)|January 23, 2014
Prox1 ablation in hepatic progenitors causes defective hepatocyte specification and increases biliary cell commitmentAsha Seth, Jianming Ye, Nanjia Yu, et al.
The Journal of Clinical Investigation|December 24, 2005
Suppression of oxidative metabolism and mitochondrial biogenesis by the transcriptional corepressor RIP140 in mouse adipocytesAimee M Powelka, Asha Seth, Joseph V Virbasius, et al.
American Journal of Physiology. Endocrinology and Metabolism|July 15, 2005
Neuromedin U has a physiological role in the regulation of food intake and partially mediates the effects of leptinPreeti H Jethwa, Caroline J Small, Kirsty L Smith, et al.
Endocrinology|March 18, 2003
Paraventricular nucleus administration of calcitonin gene-related peptide inhibits food intake and stimulates the hypothalamo-pituitary-adrenal axisWaljit S Dhillo, Caroline J Small, Preeti H Jethwa, et al.
Cell Metabolism|September 5, 2007
The transcriptional corepressor RIP140 regulates oxidative metabolism in skeletal muscleAsha Seth, Jennifer H Steel, Donna Nichol, et al.
Kidney360|December 12, 2025
Targeting αvβ8 Integrin with Monoclonal Antibody MEDI8367 Prevents Fibrosis in Preclinical Models of CKDElena Liarte Marin, Asha Seth, Lihuan Liang, et al.
The Journal of Clinical Investigation|August 9, 2014
Hypomorphism in human NSMCE2 linked to primordial dwarfism and insulin resistanceFelicity Payne, Rita Colnaghi, Nuno Rocha, et al.
Endocrinology|March 25, 2006
Neuromedin U partially mediates leptin-induced hypothalamo-pituitary adrenal (HPA) stimulation and has a physiological role in the regulation of the HPA axis in the ratPreeti H Jethwa, Kirsty L Smith, Caroline J Small, et al.
Kidney International Reports|June 20, 2024
Inhibition of Interleukin-33 to Reduce Glomerular Endothelial Inflammation in Diabetic Kidney DiseaseAlexis Hofherr, Elena Liarte Marin, Barbara Musial, et al.
RMD Open|October 6, 2025
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trialPatrick G Gavin, Erik L Allman, David Jayne, et al.
Pageof 2